During the past decade, CHU de Limoges conducted 502 clinical trials. In the 10-year time frame, 502 clinical trials started and 52 clinical trials were completed, i.e. on average, 10.4% percent of trials that started reached the finish line to date. In the past 5 years, 259 clinical trials started and 36 clinical trials were completed. i.e. 13.9% of trials that started reached the finish line.

Out of the total clinical trials conducted in "CHU de Limoges" #1 sponsor was "University Hospital, Limoges" with 110 trials, followed by "UNICANCER" with 33 trials sponsored, "Groupe Francophone des Myelodysplasies" with 26 trials sponsored, "University Hospital, Toulouse" with 24 trials sponsored and "Nantes University Hospital" with 24 trials sponsored. Other sponsors include 532 different institutions and companies that sponsored additional 215 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "CHU de Limoges" #1 collaborator was "Ministry of Health, France" with 21 trials as a collaborator, "Novartis" with 10 trials as a collaborator, "National Cancer Institute, France" with 9 trials as a collaborator, "Roche Pharma AG" with 9 trials as a collaborator and "Pfizer" with 8 trials as a collaborator. Other collaborators include 366 different institutions and companies that were collaborators in the rest 267 trials.

According to Clinical.Site data, the most researched conditions in "CHU de Limoges" are "Breast Cancer" (22 trials), "Myelodysplastic Syndromes" (21 trials), "Acute Myeloid Leukemia" (20 trials), "Amyotrophic Lateral Sclerosis" (18 trials) and "Multiple Myeloma" (15 trials). Many other conditions were trialed in "CHU de Limoges" in a lesser frequency.

Most popular intervention types in "CHU de Limoges" are "Drug" (415 trials), "Other" (156 trials), "Procedure" (72 trials), "Device" (57 trials) and "Biological" (36 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (69 trials), "radiation therapy" (15 trials), "fluorouracil" (13 trials), "Lenalidomide" (12 trials) and "placebo" (12 trials). Other intervention names were less common.

The vast majority of trials in "CHU de Limoges" are 673 trials for "All" genders, 65 trials for "Female" genders and 13 trials for "Male" genders.

Currently, there are 279 active trials in "CHU de Limoges". 13 are not yet recruiting, 191 are recruiting, 73 are Active, not recruiting, and 2 are Enrolling by invitation. In total, there were 348 completed trials in CHU de Limoges, 2 suspended trials, and 58 terminated clinical trials to date.

Out of the total trials that were conducted in CHU de Limoges, 25 "Phase 1" clinical trials were conducted, 194 "Phase 2" clinical trials and 215 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 37 trials, and there were also 138 trials that are defined as “Not Applicable".

CHU de Limoges has several departments that took part in Clinical trials: "Hopital Dupuytren; Oncologie Medicale" - 11 trials, "Hopital Uni Ire Dupuytren; Hematologie" - 6 trials, "CHU de Limoges - Fédération Hépatologie" - 5 trials, "Médecine Interne A" - 4 trials, "Service de Neurologie, CHU Limoges," - 4 trials, "Hopital Dupuytren; Pneumologie" - 3 trials, "Service de néphrologie" - 2 trials, "Pediatric emergency department" - 2 trials, "Hopital Dupuytren; Dermatologie" - 2 trials, "Centre SLA Limoges - Service de Neurologie" - 2 trials